No annual revenue total was found in CDT EQUITY INC.'s SEC filings.
CDT Equity Inc. (CDT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $747,000 in cash and investments and $45,000 in total debt.
Revenue
—
Net income (TTM)
$-37.15M
-89.1% vs year-ago TTM
Operating cash flow (TTM)
$-11.48M
+6.8% vs year-ago TTM
Free cash flow
$-9.73M
EPS (TTM)
$-202.32
-124.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.86M
-27.1% vs prior year
Net cash
$702,000
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CDT (Nasdaq), CDTTW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Naples, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1896212
- Former names
- CONDUIT PHARMACEUTICALS INC. (until Aug 7, 2025); Murphy Canyon Acquisition Corp. (until Sep 21, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$36.8M | -$15.4M | -$5.3M | -$3.2M |
| Net income | -$39.2M | -$17.8M | -$535,000 | -$4.9M |
| Diluted EPS | -$1,177.89 | -$61,598.62 | -$8.92 | — |
| Operating cash flow | -$15.6M | -$9.7M | -$7.7M | -$2.3M |
| Free cash flow | — | -$9.7M | — | — |
| Total assets | $5.7M | $4.2M | $7.2M | $5,000 |
| Total liabilities | $12.8M | $11.0M | $7.7M | $10.1M |
| Stockholders' equity | -$7.2M | -$6.8M | -$457,000 | -$10.1M |
| Cash and investments | $1.5M | $4.8M | $4.2M | $345,777 |
| Total debt | $115,000 | $226,000 | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Nov 4, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 27, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 13, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 25, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 18, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 4, 2026 | Aug 31, 2026 |
All 368 CDT Equity Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.